Celgene Posts Notice on 340B Program Website

by Admin | January 30, 2015 3:44 pm

January 30, 2015—The biotech company Celgene, acting at the request of the Health Resources and Services Administration, has posted a notice on the 340B program website explaining why it has stopped adding providers to its limited distribution networks for three of its products, including its top-selling blood cancer drug Revlimid.   

You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register[1].    Already registered? Click here to login[2]. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)

 

 

Endnotes:
  1. Click here to register: https://secure.340bhealth.org/340Binformed/Subscribe.aspx
  2. Click here to login: http://340binformed.org/reader-login/

Source URL: https://340binformed.org/2015/01/celgene-posts-notice-on-340b-program-website/

Copyright ©2026 340binformed.org unless otherwise noted.